Eli Lilly has expanded its relationship with Abbisko Therapeutics, committing up to $1.9 billion to leverage the Shanghai-based biotech’s drug discovery and early development capabilities, built on a multi-dimensional platform integrating computational chemistry, cancer genomics, and translational science, across multiple undisclosed targets, Fierce Biotech reported. The deal, announced on June 24, is the latest and largest in a wave of agreements between Western pharmaceutical giants and Chinese AI-driven biotech firms, a trend that is reshaping how the global pharmaceutical industry approaches early-stage research.
AbbVie and Lilly first partnered in 2022 to collaborate on a small-molecule drug candidate, a cardiometabolic program, co-owned under the designation P151. The expanded relationship broadens Lilly’s exposure to Abbisko’s capabilities significantly. Under the new agreement, Abbisko will perform discovery and early development work on multiple targets chosen by Lilly, with the specific targets and therapeutic areas not yet disclosed. The arrangement gives Lilly access to Abbisko’s platform without requiring it to reveal its internal pipeline priorities publicly.
Abbisko’s Computational Discovery Platform
Abbisko’s core competitive advantage is a multi-dimensional drug discovery platform that combines computational and medicinal chemistry with cancer genomics, screening, and translational science. The company uses this integrated approach to identify novel binding sites on disease-relevant proteins, generate candidate molecules optimized for potency and selectivity, and predict the pharmacokinetic properties that determine whether a drug candidate will behave safely and effectively in the human body.
This approach is particularly valuable for multi-target programs, drugs designed to modulate multiple biological pathways simultaneously. Multi-target therapeutics are harder to design using traditional methods because the optimization problem becomes exponentially more complex as the number of targets increases. AI-assisted design can navigate this complexity more efficiently, identifying molecules that satisfy multiple constraints at once.
Abbisko’s in-house preclinical pipeline demonstrates the breadth of the platform’s application. The company has a GIPR obesity program that targets the same pathway as some of the most commercially successful drugs in pharmaceutical history, a STAT6 project focused on eczema and lung diseases, and a slate of solid tumor candidates. The diversity of this pipeline across metabolic, inflammatory, and oncology indications reflects the platform’s generality rather than a narrow focus on a single disease area.
The Financial Structure of the Deal
Lilly is paying an undisclosed upfront fee to Abbisko. Beyond that, Abbisko is eligible to receive up to $1.9 billion in development, regulatory, and commercial milestones, as well as tiered royalties on annual net sales. The milestone structure is back-loaded, meaning that the majority of the $1.9 billion is contingent on clinical and commercial success, a standard arrangement in pharmaceutical licensing that aligns the interests of both parties.
The deal continues Lilly’s aggressive pace of dealmaking, which has been fueled by the extraordinary commercial success of its GLP-1 drugs, Mounjaro and Zepbound. In the past month alone, Lilly has struck deals to acquire three vaccine developers for up to $3.8 billion, buy neuroscience startup 4E Therapeutics for an undisclosed amount, and ink licensing pacts with AlzeCure, Ascidian Therapeutics, Haisco Pharmaceutical, and Hanmi Pharm. The Abbisko deal adds to a dealmaking sprint that reflects both Lilly’s financial strength and its recognition that external innovation is essential to sustaining its pipeline.
A Broader Wave of Western Pharma Deals with Chinese AI Biotechs
The Lilly-Abbisko deal is part of a broader pattern that has accelerated significantly in 2026. Last month, Bristol Myers Squibb and Pfizer both struck deals to funnel certain internal programs through the early development capabilities of Chinese partners. The common thread in these transactions is the recognition that China has developed a genuine competitive advantage in AI-assisted drug discovery — combining large pools of biological data, strong computational infrastructure, and a generation of scientists trained at the intersection of machine learning and life sciences.
China’s NMPA issued “AI + Drug Regulation” rules in 2026 to overhaul pharmaceutical review by 2030, creating a regulatory framework that is designed to accelerate the approval of AI-discovered drugs. This regulatory tailwind makes China an increasingly attractive location for early-stage drug development, particularly for programs that can benefit from faster iteration cycles and lower clinical trial costs.
The Geopolitical Dimension
The wave of Western pharma deals with Chinese AI biotechs is not without controversy. Some US lawmakers have raised concerns about the transfer of pharmaceutical intellectual property to Chinese companies, and the broader debate about technology decoupling creates an uncertain backdrop for these partnerships. The Lilly-Abbisko deal involves Lilly choosing the targets and Abbisko performing the discovery work, a structure that limits the transfer of Lilly’s most sensitive pipeline information while still capturing the value of Abbisko’s AI platform.
Whether this arrangement satisfies the concerns of regulators and policymakers who are scrutinizing US-China technology partnerships will be an important question to watch. The pharmaceutical industry has historically been less subject to export control scrutiny than the semiconductor or AI software industries, but the growing recognition of AI’s role in drug discovery is attracting greater attention from national security-focused reviewers.
For now, the commercial logic of the deal is clear. Lilly gets access to a proven AI drug discovery platform at a fraction of the cost of building equivalent capabilities in-house. Abbisko gets the financial resources and validation that come with a partnership with one of the world’s most successful pharmaceutical companies. And the broader pharmaceutical industry gets another data point suggesting that AI-powered drug discovery, delivered through Chinese biotech partnerships, is becoming a standard tool in the Western pharma playbook.